BCR-ABL fusion protein
Response and Resistance to BCR-ABL1-Targeted Therapies
shRNA Loss-of-Function Screen Identifies Alternate Pathway for BCR-ABL - Cellecta
Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistance | Haematologica
Differential signaling networks of Bcr–Abl p210 and p190 kinases in leukemia cells defined by functional proteomics | Leukemia
Bcr-Abl and Imatinib (STI571 or Gleevec) - Proteopedia, life in 3D
Regulatory Molecules and Corresponding Processes of BCR-ABL Protein Degradation
Regulatory Molecules and Corresponding Processes of BCR-ABL Protein Degradation
The Paradigm of Targeting an Oncogenic Tyrosine Kinase: Lesson from BCR-ABL | IntechOpen
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia | Nature Reviews Cancer
Differential signaling networks of Bcr–Abl p210 and p190 kinases in leukemia cells defined by functional proteomics | Leukemia
IJMS | Free Full-Text | Blockade of Y177 and Nuclear Translocation of Bcr- Abl Inhibits Proliferation and Promotes Apoptosis in Chronic Myeloid Leukemia Cells
Modern Therapy of Chronic Myeloid Leukemia | IntechOpen
STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia - ScienceDirect
BCR-ABL signaling mimics growth factor activation. Growth factors are... | Download Scientific Diagram
Schematic representation of the Bcr-Abl tyrosine kinase.
The tyrosine kinase c-Abl potentiates interferon-mediated antiviral immunity by STAT1 phosphorylation - ScienceDirect
Schematic representation of the mechanism of action of the BCR-ABLTKIs.... | Download Scientific Diagram
![PDF] STI571: targeting BCR-ABL as therapy for CML. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/abe5044fe80e8c71cb173b7772cc9a1ead53fc71/2-Figure1-1.png "PDF] STI571: targeting BCR-ABL as therapy for CML. | Semantic Scholar")
PDF] STI571: targeting BCR-ABL as therapy for CML. | Semantic Scholar
Bcr-Abl and Imatinib (STI571 or Gleevec) - Proteopedia, life in 3D
Hematology Reports | Free Full-Text | Outcomes of the Pregnancies with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era and Literature Review
Dasatinib is an Orally Active Dual Bcr-Abl and Src Family Tyrosine Kinase Inhibitor | MedChemExpress
Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis - ScienceDirect
